Document Detail

Comparison of renin-angiotensin to calcium channel blockade in renal disease.
MedLine Citation:
PMID:  9407414     Owner:  NLM     Status:  MEDLINE    
Whether any class of antihypertensive drugs has specific renoprotective effects above and beyond lowering of blood pressure is still debatable. The renin-angiotensin system (RAS) is both localized and has many actions within the kidney, on intrarenal hemodynamics, on the mesangial cell, as well as stimulating growth factors and cytokines. Angiotensin converting enzyme (ACE) inhibitors have been shown to ameliorate the progression of renal failure. How much of this beneficial effect is due to their hemodynamic effects, how much to non-hemodynamic effects and how much to their effects on bradykinin and other putative ACE substrates is still unclear. Experimentally it can be shown that inhibiting ACE but preventing the fall in systemic blood pressure by salt loading abolishes renoprotection. Bradykinin has been implicated in both the beneficial and the adverse effects of ACE inhibitors. Because of this and because ACE inhibitors may not provide complete blockade of the RAS, angiotensin receptor (AT1R) antagonists have been developed. Experimentally AT1R antagonists have been shown to reproduce most of the beneficial effects of ACE inhibitors. The experience in humans is more limited but they have been demonstrated to be efficacious in hypertension, to reduce proteinuria, and produce a favorable hemodynamic effect in congestive cardiac failure with a low incidence of adverse effects and without cough. Calcium channel blockers (CCB) also have additional properties that may provide renoprotection beyond lowering blood pressure. However, as the different types of CCB block different calcium channels their effects may differ substantially. The inconsistency of the data in the renoprotective effect of CCB may reflect these differences. Quantitatively probably the most important factor in preventing the progress of renal failure by antihypertensive drugs is strict control of blood pressure. Lowering blood pressure by drugs is most likely effective by both reducing physical and sheer stress damage, as well as turning off the signal for the activation and production of vasoactive peptides and cytokines.
I Tikkanen; C I Johnston
Related Documents :
6282024 - Fluctuations in the plasma angiotensin i converting enzyme activity during long-term tr...
9695724 - Differential responses of the heart and vasculature to chronic blood pressure reduction...
23710904 - A study of pathophysiological factors associated with gastro-esophageal reflux disease ...
232084 - Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin con...
2708814 - The measurement of internal ph in resistance arterioles: evidence that intracellular ph...
3767034 - Pulmonary and systemic hemodynamic effects of nitrous oxide in infants with normal and ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Kidney international. Supplement     Volume:  63     ISSN:  0098-6577     ISO Abbreviation:  Kidney Int. Suppl.     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1998-02-05     Completed Date:  1998-02-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7508622     Medline TA:  Kidney Int Suppl     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S19-22     Citation Subset:  IM    
Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / antagonists & inhibitors*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Calcium Channel Blockers / therapeutic use*
Hypertension, Renovascular / drug therapy,  physiopathology
Kidney Diseases / drug therapy*,  physiopathology
Renin-Angiotensin System / drug effects*,  physiology
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 11128-99-7/Angiotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High normo- or low microalbuminuria: basis for intervention in insulin-dependent diabetes mellitus.
Next Document:  Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE i...